A Phase 2 interventional study of Colchicin 0.5 mg once daily for two weeks, then twice daily for two weeks and Placebo once daily for two weeks, then twice daily for two weeks in Type 1 Diabetes, Chronic Inflammation and Insulin Sensitivity, sponsored by Asger Lund, MD. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Asger Lund, MD · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark — 30 open to participants now, 35 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · Denmark.
Among the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, this one is the 93rd largest by planned enrollment of the 157 interventional ones that give a count, is one of 11 that started in 2025, is one of 16 in phase 2, reaches primary completion later than 13 of the 34 other live ones, and was the 185th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →30 of the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark are open now. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 2–18
Steno Diabetes Center Copenhagen · Sites in Denmark
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18+
Klavs Würgler Hansen · Sites in Denmark
Ages 18+
Henrik Bo Wiberg Larsson · Sites in Denmark, Germany
Ages 50–80 · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
196 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 20 · Phase 3 34 · Phase 4 19
First in 1995; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 26 is below the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 157 interventional studies, 175 across the 38 observational. Of the 147 that completed or were terminated, 28 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 196 have an industry lead sponsor. The 10 most frequent:
Asger Lund, MD is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Asger Lund, MD has 4 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
11 of the studies in Diabetes Mellitus, Type 1 with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07247734Asger Lund, MDThe Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation | 2026-12-22 |
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
| NCT07172672University of AarhusThe TiMeD-T1D Project | 2027-02-01 |
| NCT06111586SanofiFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS) | 2027-04-28 |
Add all 11 to your calendar (.ics) → With an account.
Among the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim for this clinical trial is to evaluate if colchicine in addition to standard of care improves insulin sensitivity in individuals with type 1 diabetes, systemic low-grade inflammaiton and reduced insulin sensitivity. The insulin sensitivity will be evaluated by a hyperinsulinemic, euglycemic clamp.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Regarding fertile women:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Colchicine daily for 4 weeks, followed by an 8-week washout period, then placebo for 4 weeks.
Drug: Colchicin 0.5 mg once daily for two weeks, then twice daily for two weeks · Drug: Placebo once daily for two weeks, then twice daily for two weeks
Placebo for 4 weeks followed by an 8-week washout period, then Colchicine daily for 4 weeks.
Drug: Placebo once daily for two weeks, then twice daily for two weeks · Drug: Colchicine tablet 0.5 mg once-daily for two weeks, then twice daily for two weeks
Colchicine treatment in the first period
Also known as: Colrefuz
Placebo treatment in the first period
Colchicine treatment in the second period
Placebo treatment in the second period
Mean difference in M-value
Mean difference in insulin sensitivity is measured by the M-value (glucose infusion rate mg/kg/min) during the last 30 minutes of a 180 minutes hyperinsulinemic euglycemic clamp procedure using insulin infusion rate of 60 mU/m²/min
Time frame: Four weeks of treatment comparing colchicine to placebo.
Mean difference in M-value
Measured in mg/m²/min. Adjusted to body surface area (BSA)
Time frame: After four weeks of placebo/colchicine
Mean difference in M-value (adjusted to fat free mass (FFM))
Measured in mg/kg FFM/min
Time frame: After four weeks of placebo/colchicine
Mean difference in Insulin Sensitivity Index (ISI)
Glucose infusion rate / Plasma insulin in steady state
Time frame: After four weeks of placebo/colchicine
Mean difference in average daily insulin dosage
Units/day. Total daily dose, short acting, long acting
Time frame: During four weeks of placebo/colchicine
Fold difference in Insulin sensitivity by estimated glucose disposal rate (eGDR)
Ratio. It is calculated using clinical variables such as waist circumference, hypertension status, and HbA1c. Higher eGDR values indicate better insulin sensitivity
Time frame: After four weeks of placebo/colchicine
Fold difference in fasting serum/plasma concentrations of C-reactive protein (CRP) measured by a high-sensitivity assay (hsCRP) (mg/L)
Ratio
Time frame: After four weeks of placebo/colchicine
Fold difference in in fasting serum/plasma concentrations iInterleukin 6 (IL-6) (pg/mL)
Ratio
Time frame: After four weeks of placebo/colchicine
Fold difference in in fasting serum/plasma concentrations of tumour necrosis factor alpha (TNF alpha)
Ratio
Time frame: After four weeks of placebo/colchicine
Mean difference in respiratory exchange ratio between basal state and during clamp
Ratio
Time frame: After four weeks of placebo/colchicine
Adipocyte tissue biopsies
Ratio. Fold difference in Adipocyte size, Inflammation, Glucose metabolism, Extracellular matrix, Oxygen consumption, Transcriptomics, Proteomics
Time frame: After four weeks of placebo/colchicine
Time spent in target blood glucose range (3.9 - 10 mmol/L) evaluated by a continous glucose monitor (CGM)
Measured in % of 24 hours.
Time frame: The last 7 days of each treatment period.
Time spent in tight range (3.9 - 7.8 mmol/L) evaluated by a continous glucose monitor (CGM)
Measured in % of 24 hours.
Time frame: The last 7 days of each treatment period.
Time spent in hyperglycemia level 1 (10-13.9 mmol/L) evaluated by a continous glucose monitor (CGM)
Measured in % of 24 hours.
Time frame: The last 7 days of each treatment period.
Time spent in hyperglycemia level 2 (> 13.9 mmol/L) evaluated by a continous glucose monitor (CGM)
Measured in % of 24 hours.
Time frame: The last 7 days of each treatment period.
Time spent in hypoglycemia level 1 (3.0-3.8 mmol/L) evaluated by a continous glucose monitor (CGM)
Measured in % of 24 hours.
Time frame: The last 7 days of each treatment period.
Time spent in hypoglycemia level 2 (< 3.0 mmol/L)evaluated by a continous glucose monitor (CGM)
Measured in % of 24 hours.
Time frame: The last 7 days of each treatment period.
Change in glycaemic variability assessed as coefficient of variance (CV)
%-point
Time frame: The last 7 days of each treatment period.
Change in standard deviation evaluated by a continous glucose monitor (mmol/L)
%-point
Time frame: The last 7 days of each treatment period.
Mean difference in Body mass index (BMI)
kg/m²
Time frame: After four weeks of placebo/colchicine
Fold difference in waist-hip ratio
After four weeks of placebo/colchicine
Time frame: ratio
Mean difference in waist circumference
Cm
Time frame: After four weeks of placebo/colchicine
Mean difference in systolic blood pressure
mmHg
Time frame: After four weeks of placebo/colchicine
Mean difference in diastolic blood pressure
mmHg
Time frame: After four weeks of placebo/colchicine
Mean difference in heart rate
beats per minute
Time frame: After four weeks of placebo/colchicine
Fold difference in body composition (fat-free mass, total fat mass, visceral fat mass rating and bone mass) as measured by bioimpedance
Ratio
Time frame: After four weeks of placebo/colchicine
Fold difference in fasting serum/plasma concentrations of inflammatory biomarkers
Ratio. Interleukines and other cytokines
Time frame: After four weeks of placebo/colchicine
Fold difference in fasting serum/plasma concentrations of total leukocyte count, including neutrophil, lymphocyte, basophil and eosinophil counts (10^9/L)
Ratio.
Time frame: After four weeks of placebo/colchicine
Fold difference in fasting serum/plasma concentrations of very low-density lipoprotein (VLDL) cholesterol (mmol/L)
Ratio.
Time frame: After four weeks of placebo/colchicine
Fold difference in fasting serum/plasma concentrations of hemoglobin A1c (mmol/mol)
Ratio
Time frame: After four weeks of placebo/colchicine
Fold difference in fasting serum/plasma concentrations of insulin (pmol/L)
Ratio
Time frame: After four weeks of placebo/colchicine
Fold difference fasting serum/plasma concentrations of C-peptide (pmol/L)
Ratio
Time frame: After four weeks of placebo/colchicine
Fold difference in fasting serum/plasma concentrations of glucagon (pmol/L)
Ratio
Time frame: After four weeks of placebo/colchicine
Mean difference in resting energy expenditure ratio between basal state and during clamp
Ratio. Participants undergo indirect calorimetry in the basal state and during the clamp (from 120-150 minutes)
Time frame: After four weeks of placebo/colchicine
Fold difference in FibroScan®-assessed liver steatosis (dB/m)
Ratio. Measured before- and after each treatment period.
Time frame: After four weeks of placebo/colchicine
Fold difference in Fatty Liver Index (FLI, range 0-100; higher scores indicate greater likelihood of fatty liver)
Ratio
Time frame: After four weeks of placebo/colchicine Ratio
Fold difference in Fibrosis-4 (FIB-4) score
Ratio. The Fibrosis-4 score is a non-invasive index used to estimate liver fibrosis. It is calculated using age, aspartate aminotransferase, alanine aminotransferase, and platelet count. Scale range: Typically from 0 to greater than 3.25
Time frame: After four weeks of placebo/colchicine
Fold difference in fasting coagulability as measured by thromboelastography (TEG)
Ratio. Measured before and after each treatment period.
Time frame: After four weeks of placebo/colchicine
Fold difference in fasting serum/plasma concentrations of hormones during the HIE clamp
Ratio. Insulin, C-peptide and other counter-regulatory hormones
Time frame: After four weeks of placebo/colchicine
Difference in rate of treatment-emergent AEs
Rate ratio
Time frame: From signed consent form to last clamp day (week 16-18)
Difference in rate of serious AEs (SAEs)
Rate ratio
Time frame: From signed consent form to last clamp day (week 16-18)
Difference in rate of severe hypoglycaemia (defined as hypoglycaemia with need of external assistance)
Rate ratio
Time frame: From signed consent form to last clamp day (week 16-18)
Difference in rate of diabetic ketoacidosis
Rate ratio
Time frame: From signed consent form to last clamp day (week 16-18)
Change in diabetes treatment satisfactory questionnaire, status version (DTSQs) (From 0 (min) to 6 (max), higher scores indicate a better outcome )
%-point
Time frame: At Visit 2 (week 0), Visit 3 (week 4), Visit 4 (week 12) and Visit 5 (week 16)
Change in diabetes treatment satisfactory questionnaire, change version (DTSQc) (From -3 (min) to 3 (max), higher scores indicate a better outcome
%-point
Time frame: At Visit 3 (week 4) and Visit 5 (week 16)
Change in fasting serum/plasma concentrations of hemoglobin (mmol/L)
%-point
Time frame: After four weeks of placebo/colchicine
Change in fasting serum/plasma concentrations of thrombocytes (10^9/L)
%-point
Time frame: After four weeks of placebo/colchicine
Change in fasting serum/plasma concentrations of albumin (g/L)
%-point
Time frame: After four weeks of placebo/colchicine
Change in fasting serum/plasma concentrations of potassium (mmol/L)
%-point
Time frame: After four weeks of placebo/colchicine
Change in fasting serum/plasma concentrations of sodium (mmol/L)
%-point
Time frame: After four weeks of placebo/colchicine
Change in fasting serum/plasma concentrations of creatinine (umol/L)
%-point
Time frame: After four weeks of placebo/colchicine
Change in fasting serum/plasma concentrations of creatine kinase (U/L)
%-point
Time frame: After four weeks of placebo/colchicine
Change in fasting serum/plasma concentrations of estimated glomerular filtration rate (eGFR) (mL/min/1.73 m2)
%-point
Time frame: After four weeks of placebo/colchicine
Change in fasting serum/plasma concentrations of alanine aminotransferase (U/L)
%-point
Time frame: After four weeks of placebo/colchicine
Change in fasting serum/plasma concentrations of aspartate aminotransferase (U/L)
%-point
Time frame: After four weeks of placebo/colchicine
Change in fasting serum/plasma concentrations of bilirubin (umol/L)
%-point
Time frame: After four weeks of placebo/colchicine
Change in fasting serum/plasma concentrations of amylase (units/L)
%-point
Time frame: After four weeks of placebo/colchicine
Fold difference in fasting serum/plasma concentrations of high-density lipoprotein (HDL) cholesterol (mmol/L)
Ratio.
Time frame: After four weeks of placebo/colchicine
Fold difference in fasting serum/plasma concentrations of total cholesterol (mmol/L)
Ratio.
Time frame: After four weeks of placebo/colchicine
Fold difference in fasting serum/plasma concentrations of triglycerides (mmol/L)
Ratio.
Time frame: After four weeks of placebo/colchicine
in fasting serum/plasma concentrations of lipoprotein (a) (mg/L)
Ratio.
Time frame: After four weeks of placebo/colchicine
Plan to share: No — At this stage, no final decision has been made regarding the sharing of individual participant data (IPD). While sharing de-identified data may contribute to transparency, reproducibility, and collaborative progress in type 1 diabetes and metabolic research, several factors must be considered. These include ethical and legal obligations related to participant confidentiality, the need for appropriate data-use agreements, and institutional policies on data governance. The possibility of sharing IPD will be revisited upon study completion, in alignment with ethical approvals, and journal publication policies.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 12 months is below that.
Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Colchicine
Asger Lund, MD